Wyeth Ltd has introduced Tygacil (tigecycline) in selected cities of India following its approval by the Drug Controller General of India.
Tygacil is the first antibiotic in a new class called glycylcyclines. It is indicated for use in complicated infections of the skin and soft tissue and complicated intra-abdominal infections.
Tygacil has in-vitro activity against many gram-positive and gram-negative bacteria, including multi-drug resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).
According to the company's press release, Tygacil is available as an orange lyophilised powder or cake. Each Tygacil vial contains 50 mg tigecycline lyophilised powder for intravenous infusion. The product was first approved in US in July 2005 and it has been launched in 33 countries in North America, Europe, Asia Pacific and Latin America as of May 2007.
Wyeth Ltd is the Indian subsidiary of Wyeth, one of the world's largest research-driven pharmaceutical and health care product companies. Wyeth is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide.